Adocia (ADOC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adocia (ADOC) has a cash flow conversion efficiency ratio of 14.997x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-9.25 Million ≈ $-10.82 Million USD) by net assets (€-617.00K ≈ $-721.34K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Adocia - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Adocia's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Adocia for a breakdown of total debt and financial obligations.
Adocia Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adocia ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bombay Super Hybrid Seeds Limited
NSE:BSHSL
|
0.508x |
|
Gateway Mining Ltd
AU:GML
|
-0.016x |
|
Powerlong Real Estate Holdings Limited
F:PW5
|
0.015x |
|
Ruby Tech
TWO:8048
|
0.042x |
|
ITEK Inc
KQ:119830
|
0.034x |
|
Amica S.A.
WAR:AMC
|
0.059x |
|
Malindo Feedmill Tbk
JK:MAIN
|
-0.003x |
|
Renascor Resources Ltd
AU:RNU
|
0.003x |
Annual Cash Flow Conversion Efficiency for Adocia (2010–2024)
The table below shows the annual cash flow conversion efficiency of Adocia from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see Adocia (ADOC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-3.09 Million ≈ $-3.61 Million |
€-15.61 Million ≈ $-18.25 Million |
5.054x | +605.94% |
| 2023-12-31 | €-6.91 Million ≈ $-8.08 Million |
€-4.95 Million ≈ $-5.79 Million |
0.716x | -38.08% |
| 2022-12-31 | €-12.97 Million ≈ $-15.16 Million |
€-14.99 Million ≈ $-17.53 Million |
1.156x | -16.95% |
| 2021-12-31 | €-13.81 Million ≈ $-16.15 Million |
€-19.23 Million ≈ $-22.49 Million |
1.392x | +140.35% |
| 2020-12-31 | €6.33 Million ≈ $7.41 Million |
€-21.85 Million ≈ $-25.55 Million |
-3.450x | -902.03% |
| 2019-12-31 | €28.04 Million ≈ $32.78 Million |
€-9.65 Million ≈ $-11.29 Million |
-0.344x | -350.07% |
| 2018-12-31 | €45.85 Million ≈ $53.60 Million |
€6.31 Million ≈ $7.38 Million |
0.138x | +122.83% |
| 2017-12-31 | €36.86 Million ≈ $43.09 Million |
€-22.23 Million ≈ $-25.99 Million |
-0.603x | -96.29% |
| 2016-12-31 | €42.76 Million ≈ $49.99 Million |
€-13.14 Million ≈ $-15.36 Million |
-0.307x | -132.56% |
| 2015-12-31 | €47.05 Million ≈ $55.01 Million |
€-6.22 Million ≈ $-7.27 Million |
-0.132x | -101.08% |
| 2014-12-31 | €2.50 Million ≈ $2.93 Million |
€30.56 Million ≈ $35.73 Million |
12.200x | +2261.78% |
| 2013-12-31 | €19.13 Million ≈ $22.36 Million |
€-10.80 Million ≈ $-12.62 Million |
-0.564x | -1514.13% |
| 2012-12-31 | €23.03 Million ≈ $26.92 Million |
€919.00K ≈ $1.07 Million |
0.040x | +102.78% |
| 2011-12-31 | €4.33 Million ≈ $5.06 Million |
€-6.22 Million ≈ $-7.27 Million |
-1.436x | -209.61% |
| 2010-12-31 | €10.69 Million ≈ $12.49 Million |
€-4.96 Million ≈ $-5.79 Million |
-0.464x | -- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more